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INTRODUCTION
Circulating tumor cells (CTCs) are defined as tumor
cells circulating in the peripheral blood of patients, shed
from either the primary tumor or a metastatic site. The
presence of CTCs in the peripheral blood of cancer pa-
tients was recognized more than a century ago.(1)
In patients with breast cancer, metastasis is the main
reason for cancer mortality. Although the survival rate
has increased, thanks to early detection and improved
adjuvant therapy, the occurrence of distant metastases
remains high. Distant relapse after definitive local treat-
ment indicates that there might be undetected spread
of the tumor at the time of primary local treatment. It
has been shown that cells can be shed from the tumor
at all stages of the disease, and these cells may remain
in the patient's circulation for lengthy periods after initial
treatment of the primary tumor.(2,3) For this reasons,
researchers have been interested in CTCs because these
cells could represent an important link to the process of
metastasis. 
In addition, CTCs may become a valuable tool to refine
prognosis. Several clinical trials have established the
correlation between the presence of CTCs at diagnosis
and decreased progression free survival and overall sur-
vival in patients with breast cancer.(4,5) Furthermore,
a potential role of CTCs for the prediction of responsive-
ness of systemic chemotherapy in adjuvant setting has
been rapidly expanding. Finally, CTCs are a potential
source of biological information that can be used to pre-
dict responsiveness to various targeted agents. In this
way, a paradigm shift may be introduced in the treat-
ment strategy, from the present one that is based only
on primary tumor characteristics to the future one that
considers molecular characterization of CTCs as well.
Here we will discuss the technical aspects of different
detection methods and possible clinical application of
CTCs in patients with breast cancer. 
STRATEGY FOR CTCS DETECTION
In the past few years, much work has been carried out
to detect and quantify cancer cells in peripheral blood.
Circulating tumor cells (CTCs) are defined as tumor cells
circulating in the peripheral blood of patients. CTCs have
long been regarded as an attractive research topic. Because
of recent technological advances, it is now possible to detect
CTCs in the bloodstream. Interestingly, CTCs are present
in both of patients with metastatic disease and early stage
localized disease in patients with breast cancer. An assay
detecting CTCs seems to have significant future potential
value in the clinical management of breast cancer as a prog-
nostic marker, monitoring treatment response and selecting
target therapy. This review addresses the technical overview
of detection methods, possible clinical application and future
direction of CTCs research. 
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The key question in the evaluation of CTCs is a choice
of neoplastic markers with unique properties in cancer
cells but not in normal tissue. One of the most important
challenges is the sensitivity of assays primarily because
of the fact that CTCs are rare events with their numbers
as low as one CTC in 106-107 leukocytes,(6) and their
fragility in the blood.(7) The specificity is also a main
issue because of heterogeneity of tumors in biologic
marker expression and physical properties such as size
and density. To date, detection methods of CTCs can be
divided into nucleic-acid based techniques and a whole
cell separation (cytometric) technique.
Nucleic acid based techniques 
Genetic alterations in plasma DNA such as mutations
in proto-oncogenes, tumor suppressor genes, or aber-
rantly methylated DNA can be surrogate markers as at
least some of the DNA could have derived from the pri-
mary tumor. For example, greater amounts of amplified
MYC-N DNA were detected in patients with neuroblas-
toma compared with healthy individuals.(8) However,
the detection of tumor-associated DNA in the plasma
could indicate the presence only of circulating nucleic
acids, not necessarily CTCs. It is not possible to deter-
mine whether the DNA came from CTCs or if it is simply
being shed as free DNA from primary tumors. In addition,
DNA has a much longer plasma half-life, the presence
of circulating free DNA may reflect merely the presence
of nucleic acids, not tumor cells. A further difficulty is
that because changes such as DNA methylation occur
early in tumorigenesis, such abnormalities might be
detected in DNA shed from dysplastic lesions in patients
who do not have a neoplastic lesion.(9) Although DNA-
based CTCs detection is promising, there are many chal-
lenges to be overcome before it can be used in clinical
practice. 
The presence of CTCs can be indirectly estimated by the
detection of tumor-associated mRNA using RT-PCR.(10)
As RNA disappears quickly from the blood after cell death,
the detection of RNA likely indicates the presence of a
whole tumor cell.(11) Cytokeratin 19 seemed to be a good
surrogate marker of circulating epithelial tumor cells.(12)
Although RT-PCR has high sensitivity, the specificity
is generally low, resulting in higher false positive rates
due to contamination and expression of markers in nor-
mal cells.(13-15) Quantitative RT-PCR with multiple
specific markers might resolve the issue of the speci-
ficity, but the target mRNA transcript needs to be care-
fully selected.(9,16) Other limitations of RT-PCR based
assays include inability for further evaluation of mor-
phological analysis and molecular profiling assays of
CTCs.(17) 
Cytometric methods
Cytometric approaches isolate individual CTCs, allowing
further morphological and molecular characterization
of the cells, including steroid receptor or HER2 status.
Enrichment of epithelial tumor cells is generally needed
to increase the sensitivity to an acceptable level because
CTCs are rare event. In recent years, there have been
many efforts to devise automated technologies.
CellSearch
A CellSearch System (Veridex, Warren, USA) is an
automated device using anti-epithelial cell adhesion
molecule (EpCAM) antibody linked to small magnetic
beads as an enrichment method.(18) After immunomag-
netic enrichment, the captured cells are fluorescently
stained with monoclonal antibodies directed against pan-
cytokeratin and CD-45, a leukocyte marker. CD-45 is
used to exclude nonspecifically stained leukocytes. CTCs
are defined as cytokeratin positive and CD-45 negative.
This highly automated system has low inter-sample vari-
ability and high reproducibility.(7,19) However, the sen-
sitivity of this technique is relatively low, which currently
limits the clinical use of this system. 
CTC-chip
A CTC-chip is a microfluidic device which consists of
78,000 microposts coated with anti-EpCAM antibodies.
Sample preparation and manipulation are a critical step
in the process of detecting CTCs. To avoid losing CTCs,
a simpler procedure should be preferred. To improve the
CTCs capture sensitivity, the CTC-chip system passes
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whole blood through the coated microposts without any
additional preparation step. The captured CTCs on the
chip are identified by fluorescence microscopy after stain-
ing with an anti-cytokeratin epithelial marker with an
anti-CD-45 antibody for negative selection.(20)This single-
step system can efficiently detect CTCs as it does not
require steps for centrifugation or washing. 
AdnaTest
AdnaTest BreastCancerTM (AdnaGen, Langenhagen,
Germany) enables the immunomagnetic enrichment of
tumor cells via a mixture of beads coated with epithelial
and tumor-associated antigens.(21,22) After immuno-
magnetic enrichment, this system extracts mRNA for
a subsequent qRT-PCR procedure for the detection of
amount of epithelial cell associated mRNAs such as MUC1,
HER2, and the surface glycoprotein. The AdnaTest sys-
tem combines traditional antibody techniques with RT-
PCR and shows a higher sensitive compared to the Cell-
Search system. 
CAM method for invasive CTCs
Ficoll density gradient centrifugation is used to obtain
the mono-nucleated cells (MNCs) from whole blood, and
MNCs is subsequently seeded and cultured with Cancer
Cell Culture (CCC) media for 12 hr (Vita-AssayTM; Vitatex
Inc., Stony Brook, USA). Non-adherent cells are washed
away, and remaining cells are stained for CTCs using
fluorescein-conjugates anti EpCAM antibody with anti-
CD45 antibody. An advantage of the CAM assay is that
it detects only viable CTCs with invasive phenotype.(23)
MAINTRAC� analysis
The positive rate of CTCs varies between zero and
100% of patients with operable and metastatic disease.(9)
Recently, Pachmann et al.(24) improved the method to
avoid cell loss resulting from enrichment procedures and
centrifugation, and were able to detect an even higher
number of epithelial cells. MAINTRAC� analysis identifies
CTCs by the use of an automated laser scanning cytome-
ter after incubating the cells with fluorescent-labeled
anti-EpCAM and anti-CD 45 antibodies. CTCs are defined
as EpCAM positive and CD-45 negative. MAINTRAC�
analysis is one of the most sensitive assays with more
than 90% positive rate of CTCs in patients with early
breast cancer. However, the question then arises regard-
ing whether these epithelial cells which are detectable
in such high numbers are indeed tumor cells, and the
methodology of this analysis is still controversial.(25)
Membrane microfilter assay
A basic strategy of‘micro filter’for CTCs detection
is using a size difference between CTCs and normal blood
cells. This method enriches relatively larger CTCs in blood
cell using the filter for microscopic identification.(26)
After separation, RT-PCR is performed on the microfil-
ter. This system is relatively easy, inexpensive and highly
sensitive for CTCs enrichment. It is one of the promising
alternative technologies for the detection of CTCs. 
Fiberoptic array scanning technology (FAST) and
Epithelial immunospot (EPISPOT)
FAST system detects immunofluorescently labeled CTCs
with an automated digital microscopy imaging system.
This method is in an early stage of development and does
not require cell enrichment. 
The EPISPOT assay identifies viable tumor cells by
detecting secreted proteins such as MUC1 and CK19 after
48-hr cell culture. Dead CTCs that cannot secrete epithe-
lial-associated proteins are not identified in this sys-
tem.(27) 
From the technical point of view, CTCs research has
been limited because of low sensitivity, specificity, and
reproducibility of the detection methods. Due to the high
variability of results in CTCs detection and the discrep-
ancy of the results, a clinical use of CTCs has not yet
been established, and standardized methods are urgently
required. 
POTENTIAL CLINICAL APPLICATION OF CTCS
There are several potential clinical applications of CTCs
research in various clinical settings. At this point, several
studies have suggested a prognostic and predictive role
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for CTCs in metastatic and adjuvant/neoadjuvant setting. 
Prognostic marker
To improve stratification of breast cancer patient, many
issues remain unresolved, and new predictive and prog-
nostic factors are needed in clinical practice. About 30%
of node negative patients will present distant metastases,
whereas 40% of the patients with involved axillary lymph
nodes will survive for 10 yr without clinical recurrence.(28)
The initial CTCs status in the patient’s peripheral blood
might be an important marker for the estimation of prog-
nosis, and a negative prognostic impact associated with
the detection of CTCs during the course of breast cancer
is generally accepted. By stratifying the prognosis using
CTCs, systemic treatment could be better targeted to
patients who are most likely to relapse, thereby avoiding
unnecessary toxic therapy for lowest risk patients. 
CTCs detected by RT-PCR for CK19 mRNA have an
independent prognostic value as a marker for poor clinical
outcome in patients with breast cancers.(28-30) Pachmann
et al.(31) reported a correlation between distant relapse
and an increase in the number of CTCs. The presence of
CTCs 3-4 weeks after surgery and before the initiation
of chemotherapy was associated with shorter disease
free survival and overall survival in patients with node
negative breast cancer.(28) 
In metastatic setting, Cristofanilli et al.(18) demon-
strated that CTCs are highly prognostic. More than five
CTCs per 7.5 mL of whole blood were identified as the
threshold. Elevated CTCs at baseline predicted extremely
short median progression free survival and overall sur-
vival. Even more interesting was that patients whose
CTCs level was high at baseline and then was reduced
to below five CTCs/7.5 mL of blood at the first follow up
had similar progression free and overall survival compared
to the group that had low levels of CTCs at baseline.(4,
18,32) This result suggested that CTCs provided inde-
pendent prognostic information beyond tumor burden.
Furthermore, assessment of CTCs was suggested to be
a superior surrogate endpoint than current radiology
imaging studies for predicting overall survival in patients
with metastatic breast cancer.(33) Other researchers
also found that a detectable level of CTCs appeared to
correlate with the worse clinical course in patients with
metastatic disease.(20,34) 
However, although a potential role of CTCs as an inde-
pendent prognostic factor is generally accepted, the future
success of CTCs test competing with conventional prog-
nostic markers or growing data of multigene assay might
be controversial. 
Predictive marker-monitoring of responsiveness
for treatment
Longitudinal monitoring of the CTCs status could be
an effective strategy for measuring the therapy efficacy
and resistance and monitoring treatment response. Early
indicators of response or resistance to treatment are an
important issue in clinical practice. In addition to being
a sign of tumor cell dissemination, increases and decreases
in their number may also serve as a surrogate marker
for response to therapy.(35) Furthermore, monitoring
CTCs in blood would be an ideal strategy because its non-
invasive sampling procedure allows repeated analyses. 
For example, an increase by 10-fold or more at the end
of therapy by MAINTRAC� analysis is a strong predictor
for relapse.(36) Although patients could be monitored
for therapy response by longitudinal CTCs assay, the
ASCO group concluded that the measurement of CTCs
was not to be used to influence treatment decisions in
patients with breast cancer in the 2007 update of their
recommendations.(37)
The Southwest Oncology Group and the Breast Cancer
Intergroup of North America are now conducting a pro-
spective trial in which patients with metastatic breast
cancer who have a positive CTC count using the CellSearch
system after 1 cycle of first-line chemotherapy will be
randomly assigned to a group that will continue with the
current therapy or to a group that will switch the current
therapy to a different chemotherapeutic agent (Southwest
Oncology Group protocol S0500). This prospective trial
could solve the uncertainty in the possibility of treatment
monitoring by CTCs assay.
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CTCs in neoadjuvant setting 
The courses of neoadjuvant chemotherapy could influ-
ence the number of CTCs. In one neoadjuvant trial, the
reduction in the number of CTCs with chemotherapy
strongly predicted for the final tumor size, suggesting
that CTCs could potentially be used to monitor the res-
ponse to primary chemotherapy.(38) The correlation bet-
ween the reduction in CTCs and the final reduction in
tumor size indicates that monitoring of CTCs could pre-
dict tumor responsiveness of particular therapy and avoid
unnecessary toxicity during neoadjuvant therapy by dis-
continuing an ineffective therapy.
However, the role of CTCs in neoadjuvant setting is
unclear. For clinical use of CTCs in neoadjuvant setting,
we need long term follow up data about the correlation
between a change in the number of CTCs and patients
prognosis.
FUTURE DIRECTION
Technical challenge in CTCs assay
Recently, many investigators have reported CTCs detec-
tion methods in breast cancer patients, including one that
uses different volumes of peripheral blood and others
that use different enrichment procedures (density cen-
trifugation, filtration, immunomagnetic beads), different
methods (RT-PCR, immunocytochemistry, immunofluo-
resence) or epithelial tumor markers (cytokeratins, mucins,
mammaglobin, etc.) Thus, it is extremely difficult to com-
pare one study with others. 
In CTCs research, the main challenge lies in develop-
ment of an optimized and standard assay platform with
a reliable sensitivity, specificity and reproducibility. Once
the optimum assays are developed, techniques validated
in the laboratory should be taken into clinical setting in
the context of meticulously designed trials. 
Molecular profiling of CTCs- target treatment
selection
Ascertainment of the phenotype of CTCs also has a
potential role in tailored treatment. CTCs can exhibit
different characteristics compared to the primary tumors,
and molecular characterization of CTCs might contribute
to improving more individualized therapies.(5,39)
Many investigators are developing methods to evaluate
biologically important markers in CTCs. Treatment-relat-
ed markers such as estrogen receptor (ER) and HER2 can
also be detected in CTCs, and these phenotypic markers
are now being investigated as possible biological indicators
of target modulation. For example, HER2 status of CTCs
might be different from that of the corresponding primary
tumors.(40-42) The fact that trastuzumab is known to
have a substantial positive impact on the survival of pa-
tients with HER2 positive disease, monitoring of CTCs
for HER2 could help identify patients who would not
otherwise receive trastuzumab due to a negative HER2
status on the primary tumor to benefit from this therapy.
In terms of ER status, there has been very limited data
about comparison of the expression between primary
tumor and CTCs, which might be useful in predicting
the benefit of endocrine therapy.(43) In addition, gene-
expression profiling of CTCs might be feasible in decision
making of tailored individual treatment strategies in the
near future.
Circulating cancer stem cells
Finding tumor cells in peripheral blood raises questions
about the possibility of the existence of subset of cells
sharing many characteristics with cancer stem cells (CSCs).
According to the CSC hypothesis, at least some of the
CTCs should have properties of metastatic potential.(44)
The majority of CTCs lack the ability to metastasize. It
appears that the potential to grow into metastases may
be restricted to a small fraction of stem cells.(45) Being
a heterogeneous population, some of these cells exhibit
a more aggressive behavior by generating early metas-
tases, and CTC subpopulations may be identified and
used as predictive tools to measure patient response to
targeted agents.(46)
CONCLUSION
In conclusion, current prognostic and predictive factors
are inefficient and the information regarding CTCs could
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provide an additional clue. Although CTCs research in
breast cancer has rapidly expanded, the clinical relevance
of CTCs has not been firmly established. Further opti-
mization and standardization of CTCs detection tech-
niques could lead to the inclusion of CTCs detection in
daily clinical practice. Molecular characterization of CTCs
might open the new horizon in improving tailored treat-
ment. In the future, identify circulating cancer stem cell
may clarify the metastatic cascade and may help develop
new targets in cancer treatment. 
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